6 Startups Searching for a Cure for Alzheimer’s
Memory loss. Fatigue. Confusion. Behavior change. Alzheimer’s disease, or simply Alzheimer’s, is an incurable, crippling condition that starts with these tell-tale symptoms and ends in death three to eight years after diagnosis when your brain has turned into cauliflower. The disease is the most common form of dementia, making up 60 percent to 70 percent of all cases. If you’re keeping up with your Netflix binge list, you’ll remember it was featured in the 2014 film Still Alice where we watched Julianne Moore forget her to-do list for almost two hours. About 50 million people worldwide suffer from this condition, with 10 million more added to the roster each year and growing, according to the World Health Organization.
The total global cost of dementia in terms of healthcare and economic productivity is staggering and was estimated to be $818 billion in 2015. Searching for a cure for Alzheimer’s promises to be both disruptive and lucrative.
The Richest 1 Percent
The disease tends to hit women the hardest, with twice as many women diagnosed compared to men. Alzheimer’s also tends to be more of an issue with the middle and upper classes. A study by University of Cambridge showed that Alzheimer’s is highly correlated to populations in wealthy, highly urbanized, highly industrialized nations with good hygiene, with some researchers speculating that the illness might be initiated by bacterial inflammation brought on by underdeveloped immune systems that haven’t been exposed to microorganisms found in less hygienic environments. Better start penciling in those urban slum play dates for the kids before it’s too late.
Cause of Alzheimer’s Disease
The traditional model is that Alzheimer’s starts when a person loses the genetic lottery and inherits a set of genes that code for misshapen brain proteins called amyloid beta and tau. During the ripe years of youth when poor life decisions only cause minimal impact and regret, these defective proteins are usually broken down by the body and hardly cause any trouble. Most people are free of symptoms up until the ages of 60 to 70. When age, stress, and hard liquor catch up (sorry, MBAs), the body’s cleanup systems begin to slow down and these proteins begin building up into toxic plaques that slowly kill neurons through inflammation in the regions of the brain involved with speech, motor function, and decision-making. The process takes many decades to show up, though about 5 percent of the population is diagnosed with Early Onset Alzheimer’s at ages 40 to 50. Some companies are using artificial intelligence to detect Alzheimer’s before it hits, and even some brain interface companies are getting into the act.
Conservative treatments that target these protein plaques have shown mixed results, leading some medical researchers to look for alternative theories for how Alzheimer’s occurs. The search for a cure for Alzheimer’s has become something akin to the Wild West, as competing hypotheses continue to populate the scientific literature. With so many conflicting ideas on how to deal with Alzheimer’s, the great challenge has been finding the right target or targets that will reverse the effects of the disease. But we’ll leave the advanced theories to the bright minds of academia and medicine.
A Multi-billion Dollar Burden
Alzheimer’s may affect only a good 50 million people worldwide, with five million living in the United States alone, but the cost of treatment and care to alleviate symptoms throughout the progression of the disease have been huge. Healthcare costs have been estimated to be a whopping $277 billion annually in the United States, according to WebMD, and that doesn’t include unpaid healthcare by relatives. Some change lifestyles or even give up careers to help care for loved ones with Alzheimer’s. There’s plenty of people willing to shell out cash to make this problem go away.
So, let’s take a look at what’s brewing in the pipeline.
Immunotherapy Treatments for Curing Alzheimer’s
Founded in 2013, Alector has raised a total of $415 million after a $133 million Series E round led by Google Ventures that recently closed in July. The San Francisco-based startup was co-founded and currently led by veteran entrepreneur and neurobiologist Dr. Arnon Rosenthal. He previously founded South San Francisco-based Rinat Neuroscience, which was acquired by Pfizer for a cool $500 million in 2006. Alector is developing antibody drug technologies to target immune system receptors that could reduce early progression of Alzheimer’s, rather than simply attacking pre-existing plaques. (Immunotherapy treatments are gaining a lot of traction for combating cancer.)
The recent round will push three of its antibody drug candidates into clinical trials. Two of those drug candidates are being co-funded and co-developed with large biopharma company AbbVie (ABBV) who has already paid Alector $200 million upfront with both companies agreeing to share global profits equally.
Targeting Bacteria to Cure Alzheimer’s
Founded in 2012, Cortexyme is another San Francisco-based company that’s pulled in $100 million from the likes of Pfizer and top VC firm Sequoia Capital. The latest Series B round brought in $76 million earlier this year to bring their lead drug candidate, COR388, through two Phase I studies. Unlike other companies that are developing technologies to target the misfolded proteins found in most Alzheimer’s patients’ brains, Cortexyme has designed COR388 as a narrow-spectrum antibiotic to inhibit a bacteria that’s been found to be involved in Alzheimer’s. The two clinical trials include a cohort of 40 patients aged 20 to 70 and 36 patients aged 55 to 80 years with Alzheimer’s to test the drug’s safety profile. The latest study will conclude in mid-October of 2018. The company has plans to move onto Phase II studies by next year.
Finding a Cure for Alzheimer’s Using Yeast
Founded in 2014, Cambridge, Massachusetts-based Yumanity Therapeutics is also developing their therapies from technology spun-out of MIT. The startup has raised $82.1 million, including $31.1 million from a Series A in June. Yumanity Therapeutics relies on a technology involving bioengineered baker’s yeast that overexpresses misfolded proteins to screen for drug candidates that target these proteins. The low cost and easy use of these petri dishes full of yeast allow the company to search for compounds that correct the misfolding more quickly than previous methods. This biotechnology might just be the best thing since sliced bread.
Possible IPO in the Pipeline
Founded in 2013, Alzheon is a clinical-stage biotech startup based out of Framingham, Massachusetts that has raised a total of $37 million after a recent venture round of $15.8 million back in 2017. Alzheon’s pharmaceutical technology is based on ALZ-801, a standard oral drug that’s meant to dissolve amyloid beta plaques by inhibiting the formation of its precursor. After withdrawing an IPO offer of $81 million earlier this year, there has been speculation by analysts that Alzheon will continue to lose money following the failure of ALZ-801 to yield favorable results in Phase 3 trials.
But it looks like Alzheon is pushing to refile an IPO for $40 million and will get another chance to conduct Phase 3 trials on ALZ-801. This time they plan to target a selective group of patients bearing genetic markers for a more specific subset of Alzheimer’s keeping their lead candidate in the game.
Hitting Alzheimer’s Disease in Early Stage
Founded in 2008, AgeneBio is a pharmaceutical company based out of Indianapolis that has raised a total of $11 million to date. The company is focused on developing treatments for mild cognitive impairment (MCI), a minor condition of memory loss that precedes dementia from Alzheimer’s and other neurodegenerative diseases. AgeneBio successfully ran a Phase II clinical trial in 2014 on 34 individuals with its lead therapeutic candidate, AGB101, for MCI. AGB101 was originally designed to treat epilepsy and has a well-characterized safety profile. The trial showed improved mental performance and memory after only a two-week course of the drug. Phase 3 trials are planned for 2018. A second drug candidate that’s prepared to enter Phase I trials, GABAA, is also still in the works.
Curing Alzheimer’s with Light Therapy
Founded in 2016, early stage startup Cognito Therapeutics was also spun out from MIT. The technology relies on treating patients with a device that exposes them to hour-long ultrafast oscillating light pulses to break down amyloid beta plaques in the brain. Think LED party strobe lights set to max. After a Series A round of funding from Chinese-based Morningside Venture Capital for an undisclosed amount and support through medical device incubator TheraNova, the strobing LED technology behind Cognito Therapeutics just began Phase I/II clinical trials in April 2018 with 60 patients using a wristband ‘Flicker’ device over a six-month period. Sorry, looks like we’re not about to see Alzheimer’s-curing rave parties any time soon.
The long string of drug development failures at the Phase 3 clinical trial stage in the past 10 years has forced researchers to re-evaluate their approach to treating Alzheimer’s. The conventional hypothesis that Alzheimer’s is caused by amyloid plaques is being questioned. At any rate, university research continues to discover new causes for Alzheimer’s, including inflammation in the brain and disturbances in gut bacteria. The field is still ripe for discovery, and it shouldn’t be long before we see artificial intelligence and gene editing step up and help us find a cure for Alzheimer’s. When you’re in your golden years and all your bodily functions are giving out, you want to make sure you can at least remember the good old days.
Are you paying too much in transaction fees to your broker? Check out a brokerage firm called Zacks Trade that's offering $1 trades for U.S. stocks until 2019. After that, you'll pay just $3 a trade or a penny a share, whichever is greater. It's one of the cheapest brokers out there and you can also trade stocks on foreign stock exchanges. Click here for $1 trades on U.S. stocks until tax day 2019.